NCT04143789View on ClinicalTrials.gov

Evaluation of AP-002 in Patients With Solid Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 27, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

April 30, 2021

Conditions
Solid Tumor
Interventions
DRUG

AP-002

Dose escalation

Trial Locations (3)

60208

NOT_YET_RECRUITING

Research Institution, Chicago

63110

RECRUITING

Research Site, St Louis

77030

RECRUITING

Investigational Site, Houston

Sponsors
All Listed Sponsors
lead

Altum Pharmaceuticals INC

INDUSTRY

NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter